Phase I data suggest PLX3397 is a potential therapy for patients with advanced PVNS

15-05-2014 EurekAlert!Comments (0)

Anti-Arthritics/RheumaticsHealthHealth Medical PharmaHealth Medical PharmaMedicineOncologyPharmaceuticalRare diseasesUSA

New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.

Read more on EurekAlert!

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top